The changes of CD4+CD25+/CD4+ proportion in spleen of tumor-bearing BALB/c mice

Abstract

CD4+CD25+ regulatory T lymphocytes (TR) constitute 5–10% of peripheral CD4+ T cells in naive mice and humans, and play an important role in controlling immune responses. Accumulating evidences show that TR cells are involved in some physiological processes and pathologic conditions such as autoimmune diseases, transplantation tolerance and cancer, and might be a promising therapeutic target for these diseases.To evaluate the change of CD4+CD25+ TR cells in mouse tumor models, CD4+CD25+ subset in peripheral blood and spleen lymphocytes from normal or C26 colon-carcinoma-bearing BABL/c mice were analyzed by flow cytometry using double staining with CD4 and CD25 antibodies.The proportion of CD4+CD25+/CD4+ in spleen lymphocytes was found to be higher than that in peripheral blood lymphocytes in normal mice. No difference was observed in the proportion in peripheral blood lymphocytes between tumor bearing mice and normal mice, while there was a significant increase in the proportion in spleen lymphocytes in tumor bearing mice as compared with normal mice. Moreover, the proportion increased in accordance with the increase in the tumor sizes. The increase in the proportion was due to the decrease in CD4+ in lymphocytes, which is resulted from decreased CD4+CD25- subset in lymphocytes. Our observation suggests the CD4+CD25+/CD4+ proportion in spleen lymphocytes might be a sensitive index to evaluate the TR in tumor mouse models, and our results provide some information on strategies of antitumor immunotherapy targeting CD4+CD25+ regulatory T lymphocytes.

Photodynamic therapy plus low-dose cyclophosphamide generates antitumor immunity in a mouse model

“…In a colon carcinoma model, an expansion of T-regs was observed only in the spleen but not in peripheral blood (36). In our results we found a small, but significant, increase in T-regs in tumor-bearing mice.…”

Application of radially grown ZnO nanowires on poly-l-lactide microfibers complexed with a tumor antigen for cancer immunotherapy

“…The systemic reduction of T cells as well as the gradual increase of regulatory T cells (T Reg ) in tumor-bearing hosts have been well established. [25][26][27] In addition, immune contextures of growing tumors, especially tumor infiltrating CTLs, have been shown to correlate with clinical outcomes. 15 In the spleens of tumorbearing mice, we observed a drastic reduction of CD4 and CD8 T cells to generally less than 1 and 2% among whole splenocytes, respectively ( Fig.…”

Scaffolding of Cystine‐Stabilized Miniproteins

“…Engineered proteins with multiple epitopes that bind to either many copies of the same binding partner (multivalent) or with several different binding partners (multi-specific) are emerging as powerful agents in molecular biology based fields. [1][2][3][4][5] In therapeutics, protein-based drugs are screened for their high affinity, natural specificity and biocompatibility. [6] Even though huge advances have been made in directed evolution and rational design algorithms to engineer proteins with higher affinities and better specificities, these traditional approaches still face concrete limitations.…”

“…[4,5,8] Cochran and co-workers have worked extensively on developing such proteins that can simultaneously bind, for example, integrins with picomolar affinities [9] or integrin and VEGFR2 receptors simultaneously. [10] Advantages of using such proteins have been further detailed in a perspective article [1] and book chapter [2] written by them. Apart from therapeutics, multivalent and multi-specific proteins are also being applied in metabolic engineering as scaffolds to immobilize heterologous cascade enzymes in close proximity with each other to improve the efficiency of biosynthetic pathways.…”